Disappointing results for Imfinzi’s clinical trial in late-stage lung cancer confirmed

Today, before European stock markets’ opening time, AstraZeneca published final results concerning its Mystic Phase-III clinical trial.

Last year, group’s CEO Pascal Soriot disclosed partial results of Mystic clinical trial, which at the time was still ongoing. Results showed that Imfinzi experimental treatment had failed to meet its primary endpoint, causing the company’s shares to immediately fall.

Right after publishing partial results, Pascal Soriot invoked investors and analysts to be patient and not to pass judgment on Imfinzi before final results. Unfortunately, results published today confirm that Imfinzi does not guarantee stage-IV lung cancer patients a better survival.

It is worth mentioning that immunotherapy medicine Imfinzi has already been approved to treat early-stage lung cancer.

AstraZeneca shares fell almost 5% on the stock exchange since yesterday.


(Source: AstraZeneca)